Verastem names CEO successor. Verastem Oncology stock has USD 780.7 million value
Published on 10/20/2026 at 13:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCEO transition and funding plan
- Michael P. Bailey will become chief executive officer on January 1, 2027.
- Verastem priced a USD 250.0 million offering on October 14, 2026.
- Verastem Oncology stock trades at EUR 7.65 at 1:48 p.m. CEST at Lang & Schwarz on October 20, 2026.
- Second-quarter revenue reached USD 40.08 million in 2026.
- Verastem is scheduled to report third-quarter results on November 3, 2026.
Verastem Oncology (ISIN US92337C2035) named Michael P. Bailey as its next chief executive officer, effective January 1, 2027, while its market value stood at USD 780.7 million as of October 19, 2026. The leadership change follows the planned retirement of Daniel Paterson, according to Verastem on October 14, 2026.
Three events shaped the pipeline
On August 6, 2026, Verastem reported second-quarter revenue of USD 40.08 million and an adjusted loss of USD 0.35 per share, compared with revenue expectations of USD 22.88 million, according to MarketBeat. On October 14, 2026, Verastem priced an offering of 30,937,500 common shares at USD 8.00 each, plus pre-funded warrants, with gross proceeds expected at USD 250.0 million, according to Business Wire. On the same date, the company announced Bailey's appointment and Paterson's planned retirement.
What does the financing mean for cash?
The offering gives Verastem capital for continued development of VS-7375 and working capital, but the additional securities increase the share count. The financing therefore pairs a larger development budget with dilution risk, while the company advances a KRAS G12D program across several solid-tumor settings.
Dates investors can track
Bailey is scheduled to become CEO on January 1, 2027, and Verastem is scheduled to report third-quarter 2026 results on November 3, 2026, according to MetaCap. The company also listed an October 14, 2026 research and development update for VS-7375 on its investor site.
Stock trades during the financing reset
Verastem Oncology was trading at EUR 7.65 at Lang & Schwarz on October 20, 2026 at 1:48 p.m. CEST. The quote places the market discussion alongside a leadership handover, fresh financing and the next quarterly reporting date.
The further course of trading is shown by the continuously updated real-time quote of Verastem Oncology stock.
Verastem Oncology stock facts
- Company: Verastem, Inc.
- ISIN: US92337C2035
- Ticker: VSTM
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 1:48 p.m. CEST): EUR 7.65
- Market capitalization: USD 780.7 million (as of October 19, 2026)
- Sector / Industry: Health Care / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report Nasdaq Composite.
